IL-17A在肺脏疾病中的研究进展  

Research Progress of Interleukin-17A in Lung Diseases

作　　者：李仕来[1] 朱继金[1] LI Shilai;ZHU Jijin(Department of Emergency,the First Affiliated Hospital of Guangxi Medical University,Nanning 530021,China)

机构地区：[1]广西医科大学第一附属医院急诊科,南宁530021

出　　处：《医学综述》2020年第18期3547-3552,3558,共7页Medical Recapitulate

基　　金：“广西急诊与医学救援人才小高地、广西高校急诊医学重点实验室”开放性课题(GXJZ201405);广西壮族自治区卫生和计划生育委员会自筹经费科研课题(Z2016289);广西医科大学第一附属医院优秀医学英才培养计划(2017-11-7)。

摘　　要：白细胞介素-17A(IL-17A)是辅助性T细胞17的标志性细胞因子,可由免疫细胞和非免疫细胞分泌。IL-17A与其受体结合后激活下游通路,诱导激活趋化因子及细胞因子的分泌和激活,发挥生物学作用。IL-17A在自身免疫性疾病中发挥关键作用,同时对感染的炎症反应、组织损伤和癌症等也具有重要作用。IL-17A与肺部炎症、肺纤维化、肺移植、肺癌和肺损伤关系密切,有可能成为肺脏相关疾病的诊断标志物和治疗靶点,为预防及治疗提供新的可能性。Interleukin-17A(IL-17A)is the typical cytokine of T helper cells 17,and it can be secreted by immune cells and non-immune cells.IL-17A binds to its receptor to activate the downstream pathway,and induce and activate the secretion of chemokines and cytokines,which will play many biological functions.IL-17A plays a key role in autoimmune disease,as well as inflammatory response,tissue damage and cancers.IL-17A has been reported to have close relationship with lung infection,pulmonary fibrosis,lung transplantation,lung cancer and lung injury,and is expected to be a potential target for the diagnosis and therapy of the lung disease,providing new possibilities for the prevention and treatment.

关 键 词：肺部炎症 肺纤维化 肺移植 肺癌 肺损伤 白细胞介素-17A 

分 类 号：R563[医药卫生—呼吸系统]